-- 獨立研究機構CFRA向提供了以下研究報告。 CFRA分析師的觀點摘要如下：IQVIA公佈2026年第一季營收為41.51億美元（年成長8.4%），主要得益於強勁的商業解決方案業務成長（年成長11.6%）和穩定的研發解決方案業務表現（年成長6.2%）。調整後每股收益為2.90美元（年成長7.4%），超出預期，並高於市場普遍預期0.08美元。我們認為，研發解決方案業務的訂單表現令人鼓舞，淨新增訂單額達25億美元，訂單出貨比為1.04倍，管理層表示生物製藥市場正在趨於穩定。 IQVIA將2026年調整後每股盈餘預期上調至12.65美元至12.95美元（中位數上調0.10美元），同時重申了營收和EBITDA預期。 342億美元的已簽訂訂單儲備支撐了營收的可見性，預計未來12個月內將有89億美元轉化為實際訂單（同比增長7.6%），儘管EBITDA利潤率從23.1%下降至22.5%。我們認為，前瞻性需求指標的中高個位數成長顯示客戶需求持續強勁，同時公司透過5.52億美元的股票回購和15%的自由現金流成長（達到4.91億美元）保持了靈活性。
Related Articles
Australia
Citigroup Adjusts Price Target on Marathon Petroleum to $257 From $243, Maintains Neutral Rating
Marathon Petroleum (MPC) has an average rating of overweight and mean price target of $253.25, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $256.58, Change: $+4.04, Percent Change: +1.60%
$MPC
Research
Research Alert: Peg Reports Strong Q1 Beat; On Track For $4.2b Capex And 7% Eps Growth In 2026
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:PEG reported Q1 2026 adjusted EPS of $1.55 vs. $1.43 (+8.4% Y/Y, +8.5% vs. consensus), supported by higher PSE&G margins from regulated infrastructure investments and customer growth, partially offset by higher depreciation and interest expense. PSEG Power earnings increased due to higher realized power prices and lower O&M costs, offset by lower generation volumes. We see the company as on target for $4.2B full-year 2026 capex guidance after deploying ~$0.8B in Q1, while PEG maintained long-term targets including $24B-$28B total capex for 2026-2030 and a 6%-7.5% rate base CAGR. Management reaffirmed its 2026 EPS guidance of $4.28-$4.40, representing ~7% growth at the midpoint. Both residential electric and gas customers increased ~1% on a trailing-12-month basis, which we think reflects continued execution of the regulated investment program. Annualized dividends were increased ~6% to $2.68 for 2026. We view this as a competitive growth rate amongst Multi-Utility peers.
$PEG
Australia
Merck Completes Terns Pharmaceuticals Acquisition
Merck (MRK) said Tuesday it has completed the acquisition of Terns Pharmaceuticals after a cash tender offer at $53 per share.Terns' stock will no longer be listed on Nasdaq, it said.The deal will result in a charge to research and development expense of about $2.35 per share, included in Q2 and full year 2026 GAAP and non-GAAP results, Merck said.GAAP and non-GAAP EPS are also expected to take a hit of about $0.12 a share in 2026 on costs associated with advancing TERN-701 and costs of financing, it added.Price: $113.21, Change: $+0.10, Percent Change: +0.09%
$MRK$TERN